175 related articles for article (PubMed ID: 24297552)
1. Utilization of an EMR-biorepository to identify the genetic predictors of calcineurin-inhibitor toxicity in heart transplant recipients.
Oetjens M; Bush WS; Birdwell KA; Dilks HH; Bowton EA; Denny JC; Wilke RA; Roden DM; Crawford DC
Pac Symp Biocomput; 2014; ():253-64. PubMed ID: 24297552
[TBL] [Abstract][Full Text] [Related]
2. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
3. An Integrated Transcriptomic Approach to Identify Molecular Markers of Calcineurin Inhibitor Nephrotoxicity in Pediatric Kidney Transplant Recipients.
Rhone ET; Bardhi E; Bontha SV; Walker PD; Almenara JA; Dumur CI; Cathro H; Maluf D; Mas V
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34063776
[TBL] [Abstract][Full Text] [Related]
4. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium.
Jacobson PA; Schladt D; Israni A; Oetting WS; Lin YC; Leduc R; Guan W; Lamba V; Matas AJ;
Transplantation; 2012 Mar; 93(6):624-31. PubMed ID: 22334041
[TBL] [Abstract][Full Text] [Related]
5. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
Kuypers DR; Naesens M; de Jonge H; Lerut E; Verbeke K; Vanrenterghem Y
Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235
[TBL] [Abstract][Full Text] [Related]
7. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
8. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Nashan B; Schemmer P; Braun F; Dworak M; Wimmer P; Schlitt H
Trials; 2015 Mar; 16():118. PubMed ID: 25873064
[TBL] [Abstract][Full Text] [Related]
10. The natural history of renal function following orthotopic heart transplant.
Al Aly Z; Abbas S; Moore E; Diallo O; Hauptman PJ; Bastani B
Clin Transplant; 2005 Oct; 19(5):683-9. PubMed ID: 16146562
[TBL] [Abstract][Full Text] [Related]
11. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of conversion from calcineurin inhibitors to sirolimus in 150 maintenance kidney transplant patients.
Garrouste C; Kamar N; Guilbeau-Frugier C; Guitard J; Esposito L; Lavayssière L; Nogier MB; Cointault O; Ribes D; Rostaing L
Exp Clin Transplant; 2012 Apr; 10(2):110-8. PubMed ID: 22432753
[TBL] [Abstract][Full Text] [Related]
13. Calcineurin inhibitor-associated early renal insufficiency in cardiac transplant recipients: risk factors and strategies for prevention and treatment.
Baran DA; Galin ID; Gass AL
Am J Cardiovasc Drugs; 2004; 4(1):21-9. PubMed ID: 14967063
[TBL] [Abstract][Full Text] [Related]
14. Calcineurin inhibitor withdrawal and conversion to mycophenolate mofetil and steroids in cardiac transplant recipients with chronic renal failure: a word of caution.
Groetzner J; Kaczmarek I; Schirmer J; Uberfuhr P; Gulbins H; Daebritz S; Meiser B; Reichart B
Clin Transplant; 2008; 22(5):587-93. PubMed ID: 18460000
[TBL] [Abstract][Full Text] [Related]
15. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
16. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients.
Birdwell KA; Grady B; Choi L; Xu H; Bian A; Denny JC; Jiang M; Vranic G; Basford M; Cowan JD; Richardson DM; Robinson MP; Ikizler TA; Ritchie MD; Stein CM; Haas DW
Pharmacogenet Genomics; 2012 Jan; 22(1):32-42. PubMed ID: 22108237
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
18. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
19. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
[TBL] [Abstract][Full Text] [Related]
20. THE CHALLENGES IN USING ELECTRONIC HEALTH RECORDS FOR PHARMACOGENOMICS AND PRECISION MEDICINE RESEARCH.
Laper SM; Restrepo NA; Crawford DC
Pac Symp Biocomput; 2016; 21():369-80. PubMed ID: 26776201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
